Identification of novel ligands interacting with kappa opioid receptors by Spetea, Mariana et al.
MEETING ABSTRACT Open Access
Identification of novel ligands interacting with
kappa opioid receptors
Mariana Spetea
1*, Muhammad F Asim
1, Ilona P Berzetei-Gurske
2, Gerhard Wolber
1,3, Helmut Schmidhammer
1
From 17th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the
Hungarian Society of Experimental and Clinical Pharmacology (MFT)
Innsbruck, Austria. 29-30 September 2011
Background
The  opioid (KOP) receptor belongs to the family of
seven transmembrane G protein-coupled receptors
(GPCRs) and it plays a significant role in a broad range of
physiological functions. Stimulation of the KOP receptor
results in analgesic actions, and KOP agonists appear to
have some advantages over the μ opioid (MOP) receptor
agonists. Inhibiting KOP receptors is proposed to be useful
for treating addiction and stress-related conditions, such
as depression and anxiety. The pharmacology of currently
available KOP antagonists shows a delay in onset of action
and an extremely long duration of action in vivo,w h i c h
might limit their therapeutic application. The search for
new ligands with potent biological activities, particularly as
potential novel therapeutic agents, utilizing computational
and synthetical approaches, is a key goal of life science
research and drug development. Herein, we present the
in silico, in vitro and in vivo profiles of new molecular scaf-
folds as novel KOP receptor ligands.
Methods
LigandScout and Catalyst softwares were used to gener-
ate and validate a merged feature ligand-based 3D phar-
macophore model for KOP receptors. Biological
activities were evaluated in in vitro opioid receptor bind-
ing and [
35S]GTPgS functional assays. Antinociceptive
properties were assessed in mice using the writhing test.
Results
The integrated computational screening strategy has led
to the discovery of sewarine as KOP receptor ligand.
This phenolic alkaloid from the plant Rhazya stricta
binds with high selectivity to the KOP receptor and
shows antagonist activity. A comprehensive SAR analysis
on several analogues was pursued and primary chemical
features responsible for KOP activity have been identi-
fied. Combining synthetical and pharmacological meth-
odologies, two phenolic molecules were identified as
novel highly selective ligands interacting with KOP
receptors, and displaying full agonist or partial agonist
properties, respectively. Dose-dependent and nor-BNI-
sensitive antinociceptive effects were produced by the
KOP agonist after subcutaneous administration to mice,
exhibiting a potency comparable to that of U-50,488.
Conclusions
This study uncovers new classes of ligands interacting
with KOP receptors and sharpens the understanding of
ligand-receptor interactions, thus increasing the chance
of developing useful clinical agents among KOP ligands.
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